177Lu-PSMA-617 or a Change of ARPI for Taxane-Naive Metastatic Castration-Resistant Prostate Cancer?

Although ¹⁷⁷Lu-PSMA-617 improved radiographic progression-free survival compared with a change in androgen-receptor pathway inhibitor, the optimal timing for its use remains undefined.

¹⁷⁷Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA)–targeted radioligand therapy that is FDA approved for PSMA-positive, metastatic castration-resistant prostate cancer (mCRPC) with disease progression following treatment with an androgen-receptor pathway inhibitor (ARPI) and docetaxel. In the industry-sponsored, multinational, phase 3 PSMAfore trial, 468 patients with progressive docetaxel-naive mCRPC were randomized to switch to an alternative ARPI (abiraterone or enzalutamide) or to receive ¹⁷⁷Lu-PSMA-617 once every 6 weeks for 6 cycles.

Among the key findings:

Radiographic progression-free survival, the primary outcome, was significantly improved in the ¹⁷⁷Lu-PSMA-617 arm compared with the alternative-ARPI arm (median, 11.6 vs. …

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

¹⁷⁷Lu-PSMA-617 or a Change of ARPI for Taxane-Naive Metastatic Castration-Resistant Prostate Cancer?

Topics

Reviewing Author